The UbcH8 ubiquitin E2 enzyme is also the E2 enzyme for ISG15, an IFN-alpha/beta-induced ubiquitin-like protein - PubMed (original) (raw)

The UbcH8 ubiquitin E2 enzyme is also the E2 enzyme for ISG15, an IFN-alpha/beta-induced ubiquitin-like protein

Chen Zhao et al. Proc Natl Acad Sci U S A. 2004.

Abstract

Ubiquitin-(Ub) like proteins (Ubls) are conjugated to their targets by an enzymatic cascade involving an E1 activating enzyme, an E2 conjugating enzyme, and in some cases an E3 ligase. ISG15 is a Ubl that is conjugated to cellular proteins after IFN-alpha/beta stimulation. Although the E1 enzyme for ISG15 (Ube1L/E1(ISG15)) has been identified, the identities of the downstream components of the ISG15 conjugation cascade have remained elusive. Here we report the purification of an E2 enzyme for ISG15 and demonstrate that it is UbcH8, an E2 that also functions in Ub conjugation. In vitro assays with purified Ub E2 enzymes and in vivo RNA interference assays indicate that UbcH8 is a major E2 enzyme for ISG15 conjugation. These results indicate that the ISG15 conjugation pathway overlaps or converges with the Ub conjugation pathway at the level of a specific E2 enzyme. Furthermore, these results raise the possibility that the ISG15 conjugation pathway might use UbcH8-competent Ub ligases in vivo. As an initial test of this hypothesis, we have shown that a UbcH8-competent Ub ligase conjugates ISG15 to a specific target in vitro. These results challenge the concept that Ub and Ubl conjugation pathways are strictly parallel and nonoverlapping and have important implications for understanding the regulation and function of ISG15 conjugation in the IFN-alpha/beta response.

PubMed Disclaimer

Figures

Fig. 1.

Fig. 1.

Identification of the E2 enzyme for ISG15 conjugation. (A) Extracts from IFN-β-treated (lanes 3 and 4) or untreated (lanes 1 and 2) A549 cells were incubated with 32P-ISG15 protein in the absence (lanes 1 and 3) or presence (lanes 2 and 4) of E1ISG15 for 30 min at 25°C. The protein products were resolved by electrophoresis on a 10% polyacrylamide gel. Positions of molecular mass markers are shown on the right. (B)Affinity purification of the E2 enzyme for ISG15. Cell extract (15 mg of protein) from IFN-β-treated (lanes 1 and 3) or untreated (lane 2) A549 cells were incubated with GST-ISG15 (2 mg) in either the absence (lane 1) or presence (lanes 2 and 3) of E1ISG15 (500 μg) in a final volume of 1 ml for 30 min at 25°C under the thioester reaction conditions described in Methods. The reaction products were affinity selected on glutathione-Sepharose, and thioester bonds were cleaved by DTT treatment. The eluted proteins were subjected to electrophoresis on 15% polyacrylamide gels, followed by Coomassie blue staining. The 17-kDa protein in lane 3 was digested with trypsin, and the smallest tryptic peptide was sequenced by automated Edman degradation at the W. M. Keck Foundation Biotechnology Resource Laboratory at Yale University.

Fig. 2.

Fig. 2.

UbcH8 functions as a major E2 enzyme for ISG15 in vitro. (A) 32P-GST-ISG15 was incubated in the presence (lanes 1 and 3) or absence (lane 2) of UbcH8 and in the presence (lanes 2 and 3) or absence (lane 1) of E1ISG15. (B) Either 32P-GST-Ub (lanes 1-5) or 32P-GST-ISG15 (lanes 6-10) was incubated in the absence (lanes 1 and 6) or presence of E1Ub (lanes 2-5) or E1ISG15 (lanes 7-10) and in the absence or presence of the indicated E2 proteins.

Fig. 4.

Fig. 4.

A Ub E3 functions with ISG15 in vitro. (A) Purified FLAG-WBP2 protein was incubated with either Ub, E1Ub, and UbcH8 (lanes 1-3) or ISG15, E1ISG15, and UbcH8 (lanes 4-6), in the absence (lanes 1 and 4) or presence of Rsp5p (lanes 2 and 5) or in the presence the C-A mutant of Rsp5p (lanes 3 and 6). Reactions products were analyzed by immunoblotting with anti-FLAG antibody. (B) Conjugation reactions were performed as in A, in the presence of 32P-Ub (lanes 1 and 2) or 32P-ISG15 (lanes 3 and 4). Reaction products were immunoprecipitated with anti-FLAG antibody and analyzed by SDS/PAGE and autoradiography.

Fig. 3.

Fig. 3.

UbcH8 functions as a major E2 enzyme for ISG15 in vivo. Cells were either mock transfected (-siRNA) or transfected with an siRNA (20 nM final concentration) directed against bases 28-49 of the ORF of human UbcH8 mRNA (+siRNA lanes). After 24 h, the cells were left untreated (-IFN lanes) or were treated with IFN-β (1,000 units/ml; +IFN lanes). After another 24 h, the cells were collected. RNA was analyzed for UbcH8 mRNA by Northern analysis (Left), and proteins were analyzed by immunoblotting with ISG15 antiserum (Right). Each lane of the Northern blot contained 12 μg of total RNA, and the presence of equal amounts of RNA in each lane was confirmed by ethidium bromide staining of 28S ribosomal RNA (not shown). The same results were obtained by using a second siRNA that was directed against bases 239-258 of the ORF of UbcH8 mRNA, and an siRNA directed against a sequence in the mRNA for GFP did not decrease either UbcH8 mRNA or ISG15 conjugation (not shown).

Similar articles

Cited by

References

    1. Levy, D. E. & Garcia-Sastre, A. (2001) Cytokine Growth Factor Rev. 12, 143-156. - PubMed
    1. Haas, A. L., Ahrens, P., Bright, P. M. & Ankel, H. (1987) J. Biol. Chem. 262, 11315-11323. - PubMed
    1. Farrell, P. J., Broeze, R. J. & Lengyel, P. (1979) Nature 279, 523-525. - PubMed
    1. Loeb, K. R. & Haas, A. L. (1992) J. Biol. Chem. 267, 7806-7813. - PubMed
    1. Schwartz, D. C. & Hochstrasser, M. (2003) Trends Biochem. Sci. 28, 321-328. - PubMed

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources